scholarly journals Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma

2020 ◽  
Vol 9 (24) ◽  
pp. 9256-9265
Author(s):  
Dongbin Ahn ◽  
Gil Joon Lee ◽  
Jin Ho Sohn ◽  
Jeong Eun Lee
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Trial ◽  
Chemoradiation Therapy ◽  
Neck Squamous Cell Carcinoma ◽  
Concurrent Chemoradiation ◽  
Concurrent Chemoradiation Therapy

Phase II trial evaluating axitinib for patients with unresectable, recurrent, or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e17027-e17027 ◽  
Author(s):  
Assuntina Gesualda Sacco ◽  
Lili Zhao ◽  
Thomas E. Carey ◽  
Irina Y. Dobrosotskaya ◽  
Jonathan B. McHugh ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Trial ◽  
Neck Squamous Cell Carcinoma

scholarly journals Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

2021 ◽  
Vol 39 (1) ◽  
pp. 30-37 ◽  
Author(s):  
Sean McBride ◽  
Eric Sherman ◽  
C. Jillian Tsai ◽  
Shrujal Baxi ◽  
Jahan Aghalar ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Stereotactic Body Radiotherapy ◽  
Phase Ii Trial ◽  
Neck Squamous Cell Carcinoma ◽  
Abscopal Effect ◽  
Randomized Phase Ii

PURPOSE The objective response rate (ORR) for single-agent anti–programmed death receptor 1 (anti–PD-1) therapy is modest in patients with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). We aimed to test whether radiotherapy may act synergistically with anti–PD-1 therapy to improve response through the abscopal effect. PATIENTS AND METHODS We conducted a single-center, randomized, phase II trial of nivolumab (anti–PD-1 therapy) versus nivolumab plus stereotactic body radiotherapy (SBRT) in patients with metastatic HNSCC. Patients had at least two metastatic lesions: one that could be safely irradiated and one measurable by RECIST version 1.1. Patients were randomly assigned (1:1), stratified by human papillomavirus status, to nivolumab (3 mg/kg intravenously every 2 weeks) or nivolumab (same dose) plus SBRT (9 Gy × 3) to 1 lesion. The primary end point was ORR in nonirradiated lesions, which was assessed by RECIST in patients with at least one available set of on-treatment images; safety was assessed in a per-protocol population. RESULTS Between March 11, 2016, and June 22, 2018, 62 patients were randomly assigned to nivolumab (n = 30) or nivolumab plus SBRT (n = 32). There was no statistically significant ORR difference between arms (34.5% [95% CI, 19.9% to 52.7%] v 29.0% [95% CI, 16.1% to 46.6%]; P = .86). There was no significant difference in overall survival ( P = .75), progression-free survival ( P = .79), or response duration ( P = .26). Grade 3-5 toxicities were similar (13.3% v 9.7%; P = .70). CONCLUSION We found no improvement in response and no evidence of an abscopal effect with the addition of SBRT to nivolumab in unselected patients with metastatic HNSCC.

Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma

Oral Oncology ◽  
2018 ◽  
Vol 82 ◽  
pp. 83-90 ◽  
Author(s):  
Renata Ferrarotto ◽  
William N. William ◽  
Jennifer E. Tseng ◽  
Shanthi Marur ◽  
Dong M. Shin ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Trial ◽  
Neck Squamous Cell Carcinoma ◽  
Randomized Phase Ii
Sign in / Sign up

Export Citation Format

Share Document